🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

46 results for “INOVIO” Clear

  1. INO-1400

    INOVIO PHARMACEUTICALS, INC.

    Breast Cancer

    phase 1 mab completed

    1 trial

  2. INO-1800

    INOVIO PHARMACEUTICALS, INC.

    Hepatitis B

    phase 1 mab completed

    1 trial

  3. INO-3106, INO-9012

    INOVIO PHARMACEUTICALS, INC.

    Aerodigestive Precancerous Lesions and Malignancies

    phase 1 mab completed

    1 trial

  4. INO-3401 + EP

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial

  5. INO-3605

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial

  6. INO-4201

    INOVIO PHARMACEUTICALS, INC.

    Ebola Virus Disease

    phase 1 mab completed

    1 trial

  7. INO-4201

    INOVIO PHARMACEUTICALS, INC.

    Ebola Vaccine

    phase 1 mab completed

    1 trial

  8. INO-4500

    INOVIO PHARMACEUTICALS, INC.

    Lassa Fever

    phase 1 small molecule completed

    2 trials

  9. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    BRCA1/2 Mutation

    phase 1 small molecule active

    1 trial

  10. INO-A002

    INOVIO PHARMACEUTICALS, INC.

    Healthy Volunteers

    phase 1 mab completed

    1 trial

  11. NKTR-214 (Cohort A)

    INOVIO PHARMACEUTICALS, INC.

    Metastatic Castration-resistant Prostate Cancer

    phase 1 small molecule completed

    1 trial

  12. PENNVAX-B

    INOVIO PHARMACEUTICALS, INC.

    HIV-1 Infection

    phase 1 mab completed

    1 trial

  13. V930

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial

  14. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Human Papillomavirus (HPV)

    phase 1 mab completed

    1 trial

  15. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Papillomavirus Infections

    phase 1 mab completed

    1 trial

  16. VGX-3400

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial

  17. VGX-3400X

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial

  18. VGX-6150

    INOVIO PHARMACEUTICALS, INC.

    Hepatitis C, Chronic

    phase 1 mab completed

    1 trial

  19. dMAb AZD5396

    INOVIO PHARMACEUTICALS, INC.

    Healthy Volunteers

    phase 1 other completed

    1 trial

  20. sD-NP-GT8 DNA

    INOVIO PHARMACEUTICALS, INC.

    HIV Infections

    phase 1 mab completed

    1 trial

  21. MedPulser Electroporation with bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Cancer

    approved other completed

    1 trial

  22. Medpulser electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head and Neck Cancer

    approved other terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources